Ascentage Pharma Group International Management

Management criteria checks 2/4

Ascentage Pharma Group International's CEO is Dajun Yang, appointed in Jan 2009, has a tenure of 15.83 years. total yearly compensation is CN¥4.78M, comprised of 94.7% salary and 5.3% bonuses, including company stock and options. directly owns 0.025% of the company’s shares, worth HK$3.26M. The average tenure of the management team and the board of directors is 6 years and 5.4 years respectively.

Key information

Dajun Yang

Chief executive officer

CN¥4.8m

Total compensation

CEO salary percentage	94.7%
CEO tenure	15.8yrs
CEO ownership	0.02%
Management average tenure	6yrs
Board average tenure	5.4yrs

Recent management updates

Here's Why Ascentage Pharma Group International's (HKG:6855) CEO May Not Expect A Pay Rise This Year

May 03

Recent updates

Ascentage Pharma Group International's (HKG:6855) Shares Climb 26% But Its Business Is Yet to Catch Up

Sep 04

Here's Why Ascentage Pharma Group International (HKG:6855) Can Afford Some Debt

Aug 26

Ascentage Pharma Group International's (HKG:6855) Shares Climb 29% But Its Business Is Yet to Catch Up

Jun 18

Here's Why Ascentage Pharma Group International's (HKG:6855) CEO May Not Expect A Pay Rise This Year

May 03

Why We're Not Concerned Yet About Ascentage Pharma Group International's (HKG:6855) 30% Share Price Plunge

Mar 30

Are Investors Undervaluing Ascentage Pharma Group International (HKG:6855) By 40%?

Feb 17

There's Reason For Concern Over Ascentage Pharma Group International's (HKG:6855) Price

Dec 20

Ascentage Pharma Group International (HKG:6855) Is Making Moderate Use Of Debt

Oct 28

Some Analysts Just Cut Their Ascentage Pharma Group International (HKG:6855) Estimates

Aug 27

There's Reason For Concern Over Ascentage Pharma Group International's (HKG:6855) Price

Aug 23

Ascentage Pharma Group International (HKG:6855) Is Carrying A Fair Bit Of Debt

Jun 19

Ascentage Pharma Group International (HKG:6855) Has Debt But No Earnings; Should You Worry?

Dec 04

Is Ascentage Pharma Group International (HKG:6855) A Risky Investment?

Aug 30

Does Ascentage Pharma Group International (HKG:6855) Have A Healthy Balance Sheet?

Oct 04

CEO Compensation Analysis

How has Dajun Yang's remuneration changed compared to Ascentage Pharma Group International's earnings?
Date	Total Compensation	Salary	Company Earnings
Jun 30 2024	n/a	n/a	-CN¥360m
Mar 31 2024	n/a	n/a	-CN¥643m
Dec 31 2023	CN¥5m	CN¥5m	-CN¥926m
Sep 30 2023	n/a	n/a	-CN¥902m
Jun 30 2023	n/a	n/a	-CN¥879m
Mar 31 2023	n/a	n/a	-CN¥881m
Dec 31 2022	CN¥4m	CN¥4m	-CN¥883m
Sep 30 2022	n/a	n/a	-CN¥848m
Jun 30 2022	n/a	n/a	-CN¥812m
Mar 31 2022	n/a	n/a	-CN¥797m
Dec 31 2021	CN¥5m	CN¥5m	-CN¥782m
Sep 30 2021	n/a	n/a	-CN¥759m
Jun 30 2021	n/a	n/a	-CN¥735m
Mar 31 2021	n/a	n/a	-CN¥706m
Dec 31 2020	CN¥4m	CN¥4m	-CN¥678m
Sep 30 2020	n/a	n/a	-CN¥922m
Jun 30 2020	n/a	n/a	-CN¥1b
Mar 31 2020	n/a	n/a	-CN¥1b
Dec 31 2019	CN¥4m	CN¥3m	-CN¥1b

Compensation vs Market: Dajun's total compensation ($USD660.23K) is above average for companies of similar size in the Hong Kong market ($USD487.68K).

Compensation vs Earnings: Dajun's compensation has increased whilst the company is unprofitable.

CEO

Dajun Yang (61 yo)

15.8yrs

Tenure

CN¥4,781,000

Compensation

Dr. Dajun Yang, M.D., Ph D Co-Founded Ascentage Pharma Group International in 2019 and serves as its Chairman and has been its Director since November 17, 2017 and serves as its CEO since July 2018. His...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Dajun Yang	Co-Founder	15.8yrs	CN¥4.78m	0.025% HK$ 3.3m
Shaomeng Wang	Co-Founder	no data	CN¥1.17m	no data
Ming Guo	Co-Founder	15.5yrs	no data	no data
Thomas Knapp	Senior VP & General Counsel	5.7yrs	no data	no data
Yifan Zhai	Chief Medical Officer	no data	no data	0.041% HK$ 5.3m
Douglas Fang	Senior Vice President of Preclinical Development	no data	no data	no data
Jianfeng Wen	Senior Vice President of Pharmaceutical Science	no data	no data	no data
Raymond Kmetz	Chief Business Officer	5.8yrs	no data	no data
Yifei Zhu	Chief Commercial Officer	1.6yrs	no data	no data
Cheung Ki Wong	Company Secretary	6.3yrs	no data	no data

6.0yrs

Average Tenure

61yo

Average Age

Experienced Management: 6855's management team is seasoned and experienced (6 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Dajun Yang	Co-Founder	7yrs	CN¥4.78m	0.025% HK$ 3.3m
Shaomeng Wang	Co-Founder	7yrs	CN¥1.17m	no data
Allen S. Lichter	Chairman of the Clinical Advisory Board	1.8yrs	no data	no data
Paul A. Bunn	Member of Clinical Advisory Board	no data	no data	no data
David Sidransky	Independent Non-Executive Director	3.7yrs	CN¥510.00k	no data
Jedd D. Wolchok	Member of Clinical Advisory Board	3.6yrs	no data	no data
Arul M. Chinnaiyan	Member of Clinical Advisory Board	no data	no data	no data
Changqing Ye	Independent Non-Executive Director	5.4yrs	CN¥502.00k	no data
Dazhong Lu	Non-Executive Director	6.3yrs	CN¥25.00k	no data
Wei Ren	Independent Non-Executive Director	5.4yrs	CN¥502.00k	no data
Asher A. Chanan-Khan	Member of Clinical Advisory Board	1.8yrs	no data	no data

5.4yrs

Average Tenure

60yo

Average Age

Experienced Board: 6855's board of directors are considered experienced (5.4 years average tenure).

Ascentage Pharma Group International Management

Management criteria checks 2/4

Key information

Recent management updates

Ascentage Pharma Group International Announces Board and Committee Changes

Here's Why Ascentage Pharma Group International's (HKG:6855) CEO May Not Expect A Pay Rise This Year

Ascentage Pharma Group International, Annual General Meeting, May 10, 2024

Co-Founder recently bought HK$159k worth of stock

High number of new directors

High number of new directors

Recent updates

Ascentage Pharma Received CDE Clearance for Registrational Phase III Studies of APG-2449 for Treatment of Patients with NSCLC

First half 2024 earnings released: EPS: CN¥0.56 (vs CN¥1.47 loss in 1H 2023)

Ascentage Pharma Group International's (HKG:6855) Shares Climb 26% But Its Business Is Yet to Catch Up

Consensus revenue estimates increase by 40%

Forecast to breakeven in 2026

Here's Why Ascentage Pharma Group International (HKG:6855) Can Afford Some Debt

First half 2024 earnings released: EPS: CN¥0.56 (vs CN¥1.47 loss in 1H 2023)

New major risk - Revenue and earnings growth

Ascentage Pharma Clears to Initiate A Registrational Phase III Study of Lisaftoclax, by the Center for Drug Evaluation of China National Medical Products Administration

Ascentage Pharma Group International to Report First Half, 2024 Results on Aug 22, 2024

New minor risk - Shareholder dilution

Ascentage Pharma Group International's (HKG:6855) Shares Climb 29% But Its Business Is Yet to Catch Up

Ascentage Pharma Announces Updated Results from Three Studies of Olverembatinib (HQP1351)

New minor risk - Share price stability

Ascentage Pharma Group International Announces Board and Committee Changes

Ascentage Pharma Releases Updated Clinical Data of olverembatinib in SDH-Deficient GIST, Including a CBR of 92.3%

Ascentage Pharma Releases Latest Results from Multiple Clinical Studies of Its Lead Drug Candidates in 2024 American Society of Clinical Oncology Annual Meeting

Here's Why Ascentage Pharma Group International's (HKG:6855) CEO May Not Expect A Pay Rise This Year

Consensus EPS estimates fall by 15%

Why We're Not Concerned Yet About Ascentage Pharma Group International's (HKG:6855) 30% Share Price Plunge

Ascentage Pharma Group International, Annual General Meeting, May 10, 2024

Full year 2023 earnings released: CN¥3.28 loss per share (vs CN¥3.35 loss in FY 2022)

Ascentage Pharma Group International to Report Fiscal Year 2023 Results on Mar 27, 2024

Ascentage Pharma to Present Three Preclinical Studies at 2024 American Association of Cancer Research Annual Meeting

Are Investors Undervaluing Ascentage Pharma Group International (HKG:6855) By 40%?

Ascentage Pharma Receives Clearance from the US Food and Drug Administration to Initiate Global Registrational Phase III Trial of Olverembatinib (HQP1351) in Patients with Chronic-Phase Chronic Myeloid Leukemia

Ascentage Pharma Announces Olverembatinib Included in Newest Guidelines on Chronic Myeloid Leukemia (CML) Management from the National Comprehensive Cancer Network (NCCN)

There's Reason For Concern Over Ascentage Pharma Group International's (HKG:6855) Price

Ascentage Pharma Group International Presents Preliminary Results from A Phase II Study of Novel Drug Candidate, Olverembatinib

Ascentage Pharma Group International Releases the First Dataset of BCL-2 Inhibitor Lisaftoclax in Patients with R/R Mm, Demonstrating Encouraging ORR and VGPR

Ascentage Pharma Announces the Launch of Olverembatinib in Newly Approved Indication and the Dispatch of First Batch for the New Indication

China National Medical Products Administration Approves Olverembatinib for Treatment of Cml-Cp Patients

Ascentage Pharma Group International to Present Results from Multiple Clinical Studies of olverembatinib and APG-2575 at the 2023 American Society of Hematology(ASH) Annual Meeting, two of which have been Selected for Oral Reports

Ascentage Pharma Group International (HKG:6855) Is Making Moderate Use Of Debt

Ascentage Pharma Releases Latest Data of Pelcitoclax (Apg-1252) Combined with Osimertinib Demonstrates Potential as A New Treatment Option for Tp53-And Egfr-Mutant Nsclc

Ascentage Pharma Announces First Patient Dosed in the Registrational Phase III Study of Olverembatinib in Treatment-Naïve Patients with Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia

Ascentage Pharma Announces Global Registrational Phase III Study of Bcl-2 Inhibitor Lisaftoclax in Treatment Naïve Patients with CLL/SLL Approved by the China CDE

Consensus revenue estimates fall by 12%

Some Analysts Just Cut Their Ascentage Pharma Group International (HKG:6855) Estimates

First half 2023 earnings released: CN¥1.47 loss per share (vs CN¥1.54 loss in 1H 2022)

There's Reason For Concern Over Ascentage Pharma Group International's (HKG:6855) Price

Ascentage Pharma Announces Clearance for Global Registrational Phase III Trial

Ascentage Pharma Group International to Report First Half, 2023 Results on Aug 21, 2023

Ascentage Pharma Group International Receives Clearance from the U.S. Food and Drug Administration to Initiate A Phase 3 Registrational Trial of Lisaftoclax

Ascentage Pharma Group International Announces CDE's Approval for the Phase III Pivotal Study in China of Olverembatinib for the Treatment of Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ All)

Ascentage Pharma Group International (HKG:6855) Is Carrying A Fair Bit Of Debt

Ascentage Pharma Group International Releases Updated Data Showing APG-2449's Potential as a New Treatment for Drug-Resistant NSCLC

Ascentage Pharma Group International Recommends Breakthrough Therapy Designation in China for the Treatment of Sdh-Deficient GIST

Ascentage Pharma Group International Presents Results from Four Studies at 2023 American Society of Clinical Oncology Annual Meeting

Consensus revenue estimates decrease by 22%, EPS upgraded

Full year 2022 earnings: EPS and revenues miss analyst expectations

Ascentage Pharma Group International has completed a Follow-on Equity Offering in the amount of HKD 550.125 million.

Ascentage Pharma Group International's Third-Generation BCR-ABL Inhibitor Olverembatinib Included into the 2022 National Reimbursement Drug List

Ascentage Pharma Group International Releases Preliminary Results from a Global Phase II Study of Lisaftoclax

Ascentage Pharma Delivers Oral Report on the First Dataset from the US Study of Olverembatinib (HQP1351) with Promising Efficacy Observed in Patients Who Failed Prior Treatment with Ponatinib

Ascentage Pharma Group International (HKG:6855) Has Debt But No Earnings; Should You Worry?

Ascentage Pharma's Global Industrial Base Obtains Drug Production Enterprise License

Ascentage Pharma Group International Announces IND Approval in China for Phase I Study of APG-5918 in Patients with Advanced Solid Tumors or Hematologic Malignancies

Ascentage Pharma Group International Announces Released Results from A Phase I Study of the Investigational Inhibitor of Apoptosis Protein (Iap) Antagonist Apg-1387 in Chinese Patients with Chronic Hepatitis B

Ascentage Pharma Releases Phase I Results of Iap Antagonist Apg-1387 in an Oral Report Showing Potential for Functionally Curing Chb

Co-Founder recently bought HK$159k worth of stock

Ascentage Pharma to Present Data of Olverembatinib (HQP1351) in Three Oral Reports, Including the First Dataset from the First US Study, At the ASH Annual Meeting

Ascentage Pharma to Announce Results from First-in-Human Study of IAP Antagonist APG-1387 in an Oral Report at the AASLD Annual Meeting

Ascentage Pharma Announces Phase I/Ii Data of Olverembatinib (Hqp1351) Published in the Journal of Hematology & Oncology, Further Validating the Drug's Best-In-Class Potential

Is Ascentage Pharma Group International (HKG:6855) A Risky Investment?

First half 2022 earnings released: CN¥1.54 loss per share (vs CN¥1.53 loss in 1H 2021)

Ascentage Pharma Group International to Report Q2, 2022 Results on Aug 26, 2022

High number of new directors

Ascentage Pharma Announces Clinical Trial Application for Olverembatinib (HQP1351) Approved in Canada